Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda’s FY2019 Revenue Up 57% on Shire Buy, Underlying Growth at 1.6%
Takeda Pharmaceutical’s group sales in FY2019 rose nearly 57% over the previous year as its revenue was bolstered by its Shire buyout in January last year, but operating profit shriveled by some 58% due to acquisition-related outlays, the company said…
To read the full story
Related Article
- Takeda Ups Full-Year Profit Guidance after EU Clears Obligation to Divest SHP647
August 3, 2020
- Takeda’s April-Dec. Underlying Sales Sag 1.2% as Hemophilia Meds Falter; Outlook Lifted after Buyout Cost Adjustment
February 5, 2020
- Takeda’s Underlying Revenue Skids 0.2% in 1st Half as Rare Disease Biz Weighs
November 1, 2019
- Takeda Squeezes Projected Losses for FY2019 as Velcade Copy Lags
August 1, 2019
- Takeda Sees 18.5% Sales Rise after Shire Buy, but Braces for Losses in FY2019
May 15, 2019
BUSINESS
- Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
March 4, 2026
- Meiji’s Morcamilast Wins EU Orphan Tag for Palmoplantar Pustulosis
March 4, 2026
- Efient AGs Launched Just Ahead of 3-Month Supply Deadline
March 4, 2026
- Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…